These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36044733)
21. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors . Podoll T; Pearson PG; Kaptein A; Evarts J; de Bruin G; Emmelot-van Hoek M; de Jong A; van Lith B; Sun H; Byard S; Fretland A; Hoogenboom N; Barf T; Slatter JG J Pharmacol Exp Ther; 2023 Jan; 384(1):173-186. PubMed ID: 36310034 [TBL] [Abstract][Full Text] [Related]
22. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Babu Boga S; Alhassan AB; Yu W; Selyutin O; Yu Y; Anand R; Xu J; Kelly J; Duffy JL; Liu S; Yang C; Wu H; Cai J; Bennett C; Maloney KM; Tyagarajan S; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA Bioorg Med Chem Lett; 2020 Sep; 30(17):127390. PubMed ID: 32738973 [TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464 [TBL] [Abstract][Full Text] [Related]
24. Second-generation inhibitors of Bruton tyrosine kinase. Wu J; Liu C; Tsui ST; Liu D J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878 [TBL] [Abstract][Full Text] [Related]
25. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors. Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433 [TBL] [Abstract][Full Text] [Related]
26. Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase. Awoonor-Williams E; Rowley CN J Chem Inf Model; 2021 Oct; 61(10):5234-5242. PubMed ID: 34590480 [TBL] [Abstract][Full Text] [Related]
32. A uniquely distributed purpuric drug eruption from acalabrutinib. Truong K; Bhattacharyya A; Kim J; Wells J Australas J Dermatol; 2022 May; 63(2):e142-e144. PubMed ID: 35072264 [TBL] [Abstract][Full Text] [Related]
33. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225 [TBL] [Abstract][Full Text] [Related]
34. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice. Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286 [TBL] [Abstract][Full Text] [Related]
35. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A Elife; 2020 Nov; 9():. PubMed ID: 33226337 [TBL] [Abstract][Full Text] [Related]
36. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914 [TBL] [Abstract][Full Text] [Related]